Loading…
Loading…
BIOVF does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for BIOVF and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for BIOVF and 80,000+ other tickers.
See exactly how BIOVF's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for BIOVF and 80,000+ other tickers.
Operating under the ticker BIOVF, Swedish Orphan Biovitrum AB (publ) is a specialized biotechnology company dedicated to the research, development, manufacturing, and commercialization of pharmaceutical products. Its primary therapeutic focus areas encompass hematology, immunology, and a range of genetic and metabolic disorders, with a commercial presence across Europe, North America, and other international markets. The company's diverse portfolio includes medications addressing critical conditions such as hemophilia B (Alprolix) and hemophilia A (Elocta), thrombocytopenia (Doptelet)…
Swedish Orphan Biovitrum AB (publ) (SWOBY) Q1 2026 Earnings Call Transcript
STOCKHOLM, March 27, 2026 /PRNewswire/ -- The shareholders in Swedish Orphan Biovitrum AB (publ) (Sobi®) Reg. No. 556038-9321, are hereby summoned to the Annual General Meeting (the "Meeting"), to be held on Wednesday, 6 May 2026 at 10.00 at IVA Konferenscenter, Grev Turegatan 16, Stockholm, Sweden.
Swedish Orphan Biovitrum AB (publ) (SWOBY) Analyst/Investor Day Transcript
Swedish Orphan Biovitrum AB (publ) (SWOBY) Q4 2025 Earnings Call Transcript
Swedish Orphan Biovitrum (OTCMKTS:BIOVF - Get Free Report) and Astria Therapeutics (NASDAQ: ATXS - Get Free Report) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, earnings, institutional ownership, risk, profitability, valuation and analyst recommendations. Valuation and Earnings This table compares Swedish